title: Experimental inhibition of protamine cardiotoxicity by prostacyclin.
abstract: Twelve animals (26+/-5 kg) were subjected to the study. In this experimental study, the authors used prostacyclin to inhibit the toxic metabolite release during protamine administration. Animals were divided into two equal groups. Six animals received prostacyclin (the prostacyclin group), and the other six animals did not receive any additional treatment (the control group). All cardiac output and biochemical measurements were evaluated at baseline; before cardiopulmonary bypass; and at 5, 30, and 60 minutes after protamine administration. The measured cardiac index showed that the hearts treated with prostacyclin had satisfactory preservation of left ventricular function. Metabolic and biochemical data showed that the tumor necrosis factor level was raised significantly in the control group (20.75+/-2.2 in the control group and 13.75+/-2.5 pg/mL in the prostacyclin group). Also, E and P selectin levels were elevated in the control group, but this change was less marked in the prostacyclin group. In addition, the intracellular adhesion molecule-1 (ICAM-1) level was significantly higher in the control group than in the prostacyclin group (9.26+/-2.13 in the control group and 5.13+/-1.66 ng/mL in the prostacyclin group). The authors observed that prostacyclin inhibited the toxic mediator release during heparin reversal with protamine. This inhibition is one way of protecting the myocardium reserves from protamine cardiotoxicity.
authors.affiliation: Department of Cardiovascular Surgery, Türkiye Yüksek Ihtisas Hospital, Ankara, Turkey.
authors.forename: S F
authors.initials: SF
authors.lastname: Katircioğlu
authors.forename: T
authors.initials: T
authors.lastname: Ulus
authors.forename: B
authors.initials: B
authors.lastname: Yamak
authors.forename: Z
authors.initials: Z
authors.lastname: Saritas
authors.forename: U
authors.initials: U
authors.lastname: Yildiz
mesh_terms: D000818:Animals; D004285:Dogs; D019040:E-Selectin / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D011464:Epoprostenol / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D006494:Heparin Antagonists / Q000633:toxicity*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D019007:P-Selectin / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011479:Protamines / Q000037:antagonists & inhibitors* / Q000633:toxicity; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D019040:E-Selectin; D006494:Heparin Antagonists; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D011479:Protamines; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; D011464:Epoprostenol